Sarepta Therapeutics, Inc.
SRPTUS売上高
$1.9B
百万USD
営業利益
$-700M
百万USD
純利益
$-713M
百万USD
ROE
-62.5%
最新FY
EPS
$-7.13
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $125M | $-167M | - |
| FY2021 | Q2 | $142M | $-81M | - |
| FY2021 | Q3 | $167M | $-48M | - |
| FY2021 | FY | $612M | $-419M | - |
| FY2022 | Q1 | $189M | $-105M | - |
| FY2022 | Q2 | $211M | $-231M | $-2.65 |
| FY2022 | Q3 | $208M | $-258M | $-2.94 |
| FY2022 | FY | $844M | $-703M | $-8.03 |
| FY2023 | Q1 | $231M | $-517M | $-5.86 |
| FY2023 | Q2 | $239M | $-24M | $-0.27 |
| FY2023 | Q3 | $309M | $-41M | $-0.46 |
| FY2023 | FY | $1.1B | $-536M | $-5.80 |
| FY2024 | Q1 | $359M | $36M | $0.37 |
| FY2024 | Q2 | $361M | $6M | $0.07 |
| FY2024 | Q3 | $430M | $34M | $0.34 |
| FY2024 | FY | $1.8B | $235M | $2.34 |
| FY2025 | Q1 | $612M | $-448M | $-4.60 |
| FY2025 | Q2 | $513M | $197M | $1.89 |
| FY2025 | Q3 | $370M | $-180M | $-1.80 |
| FY2025 | FY | $1.9B | $-713M | $-7.13 |
| FY2026 | Q1 | $331M | $331M | $2.88 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $301M | $381M | $456M | $612M | $844M | $1.1B | $1.8B | $1.9B |
| 営業利益 | $-267M | $-172M | $-344M | $-706M | $-564M | $-460M | $-536M | $-268M | $218M | $-700M |
| 純利益 | $-267M | $-51M | $-362M | $-715M | $-554M | $-419M | $-703M | $-536M | $235M | $-713M |
| 総資産 | $424M | $1.3B | $1.6B | $1.8B | $3.0B | $3.1B | $3.1B | $3.3B | $4.0B | $3.3B |
| 純資産 | $337M | - | - | - | - | - | - | - | - | - |
| 自己資本 | $337M | $789M | $1.0B | $818M | $762M | $928M | $385M | $859M | $1.5B | $1.1B |
| 営業CF | - | - | $-389M | $-456M | $107M | $-443M | $-325M | $-501M | $-206M | $-205M |
| EPS | - | - | - | - | - | - | $-8.03 | $-5.80 | $2.34 | $-7.13 |
| BPS | $6.14 | $12.15 | $14.48 | $10.52 | $9.59 | $10.65 | $4.38 | $9.16 | $15.74 | $10.86 |
| ROE | -79.4% | -6.4% | -35.1% | -87.4% | -72.7% | -45.1% | -182.7% | -62.4% | 15.4% | -62.5% |